LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or in Mild Alzheimer's Disease

LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or in Mild Alzheimer's Disease

Overall Status:

Terminated

Brief Description:

The purpose of this Phase II study is to evaluate the effect of the drug LY886721, a beta-secretase inhibitor, in people with mild Alzheimer's disease or mild cognitive impairment (MCI) due to Alzheimer's who test positive for amyloid plaque.

Patient Qualifications:

Min Age

Max Age

Gender

Healthy Volunteers

55 Years

N/A

Both

No

Inclusion Criteria:

Participants with Mild Alzheimer's Disease

Mini Mental State Examination (MMSE) score of 20-26 inclusive

Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for probable Alzheimer's

Brain scan positive for the presence of amyloid beta

Clinical Dementia Rating Scale (CDR) score of 0.5 or 1

Participants with Mild Cognitive Impairment

MMSE score of 27-30 inclusive

Gradual and progressive change in memory function as reported by the participant or a caregiver during more than 6 months